Mutations in TP53 and DNA damage repair genes have a negative impact on the response to first-line systemic therapy in men with prostate cancer

被引：0
作者：
Nientiedt, C. [1 ,2 ]
Wuenschel, A. -K [3 ]
Kaczorowski, A. [3 ]
Endris, V [4 ]
Zschaebitz, S. [1 ]
Jaeger, D. [1 ]
Hohenfellner, M. [5 ]
Stenzinger, A.
Duensing, S. [3 ]
机构：
[1] NCT Natl Ctr Tumorerkrankungen Heidelberg, Med Onkol, Heidelberg, Germany
[2] Klin Innere Med Hamatol Onkol & Stammzelltranspla, Freiburg, Germany
[3] Urol Clin, Mol Uroonkol, Heidelberg, Germany
[4] Pathol Inst, Allgemeine Pathol, Heidelberg, Germany
[5] Urol Clin, Heidelberg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V836
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [21] Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide
    Antonarakis, Emmanuel S.
    Lu, Changxue
    Luber, Brandon
    Liang, Chao
    Wang, Hao
    Chen, Yan
    Silberstein, John L.
    Piana, Danilo
    Lai, Zhao
    Chen, Yidong
    Isaacs, William B.
    Luo, Jun
    EUROPEAN UROLOGY, 2018, 74 (02) : 218 - 225
  • [22] Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms
    Schulz, Eduard
    Valentin, Angelika
    Ulz, Peter
    Beham-Schmid, Christine
    Lind, Karin
    Rupp, Verena
    Lackner, Herwig
    Woelfler, Albert
    Zebisch, Armin
    Olipitz, Werner
    Geigl, Jochen
    Berghold, Andrea
    Speicher, Michael R.
    Sill, Heinz
    JOURNAL OF MEDICAL GENETICS, 2012, 49 (07) : 422 - 428
  • [23] Impact of DNA damage repair (DDR) mutations on treatment outcomes in men receiving conventional therapy for metastatic castration resistant prostate cancer (mCRPC)
    Carlson, Alex S.
    Acevedo, Rigo
    Lim, Daniel M.
    Gulati, Roman
    Yu, Evan Y.
    Schweizer, Michael Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [24] DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status
    Adamsen, Birgitte L.
    Kravik, Katherine L.
    De Angelis, Paula M.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 39 (03) : 673 - 682
  • [25] Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide.
    Antonarakis, Emmanuel S.
    Lu, Changxue
    Luber, Brandon
    Wang, Hao
    Chen, Yan
    Silberstein, John
    Piana, Danilo
    Lai, Zhao
    Chen, Yidong
    Isaacs, William B.
    Luo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [26] Cribriform and Intraductal Carcinoma of the Prostate Frequently Harbor TP53, ATM and BRCA2 Gene Mutations Among Other Homologous Recombination DNA Repair Genes
    Jain, Ekta
    Sharma, Shivani
    Aggarwal, Aditi
    Jain, Deepika
    Malik, Vipra
    Shinde, Sayali
    Dixit, Mallika
    Arora, Samriti
    Singh, Hena
    Varshney, Juhi
    Lobo, Anandi
    Amin, Mahul
    Mohanty, Sambit
    LABORATORY INVESTIGATION, 2023, 103 (03) : S747 - S748
  • [27] The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non-small cell lung cancer
    Honda, Takayuki
    Seto, Katsutoshi
    Endo, Satoshi
    Takemoto, Akira
    Tanimoto, Kousuke
    Kobayashi, Masashi
    Kitano, Masatake
    Sakakibara, Rie
    Mitsumura, Takahiro
    Ishibashi, Hironori
    Inazawa, Johji
    Tanaka, Toshihiro
    Miyazaki, Yasunari
    Okubo, Kenichi
    CANCER MEDICINE, 2023, 12 (19): : 19406 - 19413
  • [28] Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients
    Slootbeek, Peter H. J.
    Luna-Velez, Maria Victoria
    Prive, Bastiaan M.
    van der Doelen, Maarten J.
    Kloots, Iris S. H.
    Naga, Samhita Pamidimarri
    Onstenk, Hilde E.
    Nagarajah, James
    Westdorp, Harm
    van Oort, Inge M.
    Kroeze, Leonie I.
    Schalken, Jack. A.
    Bloemendal, Haiko J.
    Mehra, Niven
    THERANOSTICS, 2024, 14 (12): : 4555 - 4569
  • [29] Re: Germline DNA-Repair Gene Mutations and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Abiraterone and Enzalutamide Editorial Comment
    Antonarakis, E. S.
    Lu, C.
    Luber, B.
    Liang, C.
    Wang, H.
    Chen, Y.
    Silberstein, J. L.
    Piana, D.
    Lai, Z.
    Chen, Y.
    Isaacs, W. B.
    Luo, J.
    JOURNAL OF UROLOGY, 2018, 200 (05) : 945 - 945
  • [30] Laboratory -Prostate cancer High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-na??ve metastatic prostate cancer ?Results from a prospective pilot study using a 37 gene panel
    Nientiedt, Cathleen
    Endris, Volker
    Jenzer, Maximilian
    Mansour, Josef
    Sedehi, Nassim Tawanaie Pour
    Pecqueux, Carine
    Volckmar, Anna-Lena
    Leichsenring, Jonas
    Neumann, Olaf
    Kirchner, Martina
    Hoveida, Shirin
    Lantwin, Philippa
    Kaltenecker, Katrin
    Dieffenbacher, Svenja
    Gasch, Claudia
    Hofer, Luisa
    Franke, Desiree
    Tosev, Georgi
    Goertz, Magdalena
    Schuetz, Viktoria
    Radtke, Jan-Philipp
    Nyarangi-Dix, Joanne
    Hatiboglu, Gencay
    Simpfendoerfer, Tobias
    Schoenberg, Gita
    Isaac, Sanjay
    Teber, Dogu
    Koerber, Stefan A.
    Christofi, Georgia
    Czink, Elena
    Kreuter, Rebecca
    Apostolidis, Leonidas
    Kratochwil, Clemens
    Giesel, Frederik
    Haberkorn, Uwe
    Debus, Juergen
    Sueltmann, Holger
    Zschaebitz, Stefanie
    Jaeger, Dirk
    Duensing, Anette
    Schirmacher, Peter
    Gruellich, Carsten
    Hohenfellner, Markus
    Stenzinger, Albrecht
    Duensing, Stefan
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (07)
12345